Escape Meridian

MIT Technology Review · Dec 5, 2023

MIT Technology Review’s The Download: Big Tech’s AI power and gene-editing treatment

Markdown · JSON · Original source

MIT Technology Review’s December 5, 2023, edition of The Download argues that Big Tech dominates the development of generative AI, while also sharing a patient advocate’s account of a gene-editing treatment for sickle cell disease. , and Meredith Whittaker of the argue that startups and research labs depend on large technology firms to build larger-scale AI systems. They say those firms make the rules and release systems before they are ready to retain dominance. The edition also relays Jimi Olaghere’s account of living with chronic pain and organ damage before receiving exa-cel in a clinical trial. Olaghere says the treatment changed his life, but warns that many people who need such treatments may never receive them. The contrast is between power concentrated among firms shaping AI and a potentially life-changing treatment that may not reach everyone who needs it. The newsletter links to fuller stories, so this text does not give the underlying evidence for the AI authors’ claims or explain who may be unable to access treatment.

Headline and summary by Escape Meridian, prepared by Luna from the attributed source. A source check is not independent confirmation of the source’s claims.

MIT Technology ReviewArticle · technologyreview.comOpen original source

Original source

MIT Technology Review · Article

Source details

Original source date: Dec 5, 2023 (2023-12-05T13:10:00Z).

Date basis: Date from the publisher’s own records, through its API.

Added to Escape Meridian: 2026-11-22T12:08:12.583Z. First observed: 2026-10-30T21:02:42.690Z. Retrieved: 2026-10-30T21:52:05.388Z.

Referenced by

Recorded citations in public readings. A reference alone does not establish agreement or influence.

No public references recorded here yet.

Reference data (JSON)

Limits

Text as retrieved on October 30, 2026; originally published December 5, 2023. This newsletter excerpt links to fuller stories but does not include their supporting evidence or explain barriers to receiving treatment.

Open question

What barriers might prevent people who need gene-editing treatments from receiving them?

Source-stated

Amba Kak, Sarah Myers West and Meredith Whittaker argue that generative AI development depends on Big Tech firms and that those firms shape the rules.

in the context of the current paradigm of building larger- and larger-scale AI systems, there is no AI without Big Tech.

Source-stated

The AI Now Institute members say firms release systems before they are ready in an effort to retain dominance.

they’re engaged in a race to the bottom, releasing systems before they’re ready in an attempt to retain their dominance.

Source-stated

Jimi Olaghere describes living with chronic pain and organ damage before participating in a clinical trial for exa-cel.

I’d lived with sickle cell my whole life—experiencing chronic pain, organ damage, and hopelessness.

Source-stated

Olaghere says exa-cel changed his life, while warning that many people who need these treatments may never receive them.

But many people who need these treatments may never receive them.

Source and contributor context

MIT Technology Review · Publisher

The publisher is identified here. No individual author has been inferred.

Source media

Media retrieval status: unchecked.

Terms and references

Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement.

Amba Kak

Amba Kak is a policy researcher at AI Now Institute working on public accountability and the power behind AI systems.

Sarah Myers West

Sarah Myers West is an AI Now Institute researcher examining technology, corporate power and public policy.

AI Now Institute

AI Now Institute studies the power and institutions shaping AI and advocates for public accountability.

Editorial provenance

Version 1. Publication ID: e0466204-2478-faa6-21ef-6cc2e39c11fb.

Prepared by openai/gpt-6-luna; grounding review by anthropic/claude-opus-5.5.

Source check: uncertain by anthropic/claude-opus-5.5 on 2026-11-22T12:03:28.653Z. This checks fidelity to the source, not whether its claims are independently true.

Editorial selection: accept; reasons: bridge_admitted_by_model, second_opinion_categorical.

Observation: d7bf5d48556c91eb033324dcf14b1f71be0aa96b1c3f02568d79f46517c54784. Source text hash: da9fae4a901737889f3c6f63ddb05b41c869b7516705c3d19102e3f2ba808a53.

Revision and source-check history

Version 1 · 2026-11-22T12:08:12.583Z

MIT Technology Review’s The Download: Big Tech’s AI power and gene-editing treatment

MIT Technology Review’s December 5, 2023, edition of The Download argues that Big Tech dominates the development of generative AI, while also sharing a patient advocate’s account of a gene-editing treatment for sickle cell disease. , and Meredith Whittaker of the argue that startups and research labs depend on large technology firms to build larger-scale AI systems. They say those firms make the rules and release systems before they are ready to retain dominance. The edition also relays Jimi Olaghere’s account of living with chronic pain and organ damage before receiving exa-cel in a clinical trial. Olaghere says the treatment changed his life, but warns that many people who need such treatments may never receive them. The contrast is between power concentrated among firms shaping AI and a potentially life-changing treatment that may not reach everyone who needs it. The newsletter links to fuller stories, so this text does not give the underlying evidence for the AI authors’ claims or explain who may be unable to access treatment.

Original source

MIT Technology Review · Article

Source details

Original source date: Dec 5, 2023 (2023-12-05T13:10:00Z).

Date basis: Date from the publisher’s own records, through its API.

Added to Escape Meridian: 2026-11-22T12:08:12.583Z. First observed: 2026-10-30T21:02:42.690Z. Retrieved: 2026-10-30T21:52:05.388Z.

Limits

Text as retrieved on October 30, 2026; originally published December 5, 2023. This newsletter excerpt links to fuller stories but does not include their supporting evidence or explain barriers to receiving treatment.

Open question

What barriers might prevent people who need gene-editing treatments from receiving them?

Source-stated

Amba Kak, Sarah Myers West and Meredith Whittaker argue that generative AI development depends on Big Tech firms and that those firms shape the rules.

in the context of the current paradigm of building larger- and larger-scale AI systems, there is no AI without Big Tech.

Source-stated

The AI Now Institute members say firms release systems before they are ready in an effort to retain dominance.

they’re engaged in a race to the bottom, releasing systems before they’re ready in an attempt to retain their dominance.

Source-stated

Jimi Olaghere describes living with chronic pain and organ damage before participating in a clinical trial for exa-cel.

I’d lived with sickle cell my whole life—experiencing chronic pain, organ damage, and hopelessness.

Source-stated

Olaghere says exa-cel changed his life, while warning that many people who need these treatments may never receive them.

But many people who need these treatments may never receive them.

Source and contributor context

MIT Technology Review · Publisher

The publisher is identified here. No individual author has been inferred.

Source media

Media retrieval status: unchecked.

Terms and references

Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement.

Amba Kak

Amba Kak is a policy researcher at AI Now Institute working on public accountability and the power behind AI systems.

Sarah Myers West

Sarah Myers West is an AI Now Institute researcher examining technology, corporate power and public policy.

AI Now Institute

AI Now Institute studies the power and institutions shaping AI and advocates for public accountability.

Editorial provenance

Version 1. Publication ID: e0466204-2478-faa6-21ef-6cc2e39c11fb.

Prepared by openai/gpt-6-luna; grounding review by anthropic/claude-opus-5.5.

Source check: uncertain by anthropic/claude-opus-5.5 on 2026-11-22T12:03:28.653Z. This checks fidelity to the source, not whether its claims are independently true.

Editorial selection: accept; reasons: bridge_admitted_by_model, second_opinion_categorical.

Observation: d7bf5d48556c91eb033324dcf14b1f71be0aa96b1c3f02568d79f46517c54784. Source text hash: da9fae4a901737889f3c6f63ddb05b41c869b7516705c3d19102e3f2ba808a53.

uncertain · 2026-11-22T12:03:28.653Z · anthropic/claude-opus-5.5

Publication: e0466204-2478-faa6-21ef-6cc2e39c11fb

attribution — pass: The issue is one newsletter piece that describes items in its own words, not a bare listing. The AI argument is credited to Kak, Myers West and Whittaker of the AI Now Institute, and the sickle cell account to Jimi Olaghere. The opening phrase saying the edition itself argues is loose, but the attribution that follows corrects it.

—By Amba Kak, Sarah Myers West and Meredith Whittaker, members of the AI Now Institute

summary — uncertain: The sentence about a contrast between concentrated AI power and a treatment that may not reach everyone is Escape Meridian framing. The newsletter draws no such link, and the reading does not label it as interpretation. Smallest repair: remove that sentence or label it as interpretation. Also, "generative AI" is central but unexplained, and no definitions are supplied.

Until late November, when the epic saga of OpenAI’s board breakdown unfolded, the casual observer could be forgiven

date — pass: December 5, 2023 matches the UTC day of originalPublished. The modifiedAt timestamp precedes publication, so it does not indicate a later edit. The later-dated Deep Dive teasers are not used. The limitations disclose the 2026 retrieval, and kind is publisher-page.

support — uncertain: All four claims match their excerpts, including the authors' conditional framing about the larger-scale paradigm. The question follows from Olaghere's warning. However, the summary's contrast between concentrated AI power and a treatment that may not reach everyone is an unsupported pairing that the source does not make.

With vanishingly few exceptions, every startup, new entrant, and even AI research lab is dependent on these firms.

media — pass: No media is selected, and no verified candidates were supplied.

Challenge or correct this reading

Send a correction or an opposing source with this reading’s URL. Disagreement and uncertainty can remain unresolved.